These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33003611)

  • 21. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M; Brand E
    Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease.
    Morimoto H; Ito Y; Yoden E; Horie M; Tanaka N; Komurasaki Y; Yamamoto R; Mihara K; Minami K; Hirato T
    Mol Genet Metab; 2018 Sep; 125(1-2):153-160. PubMed ID: 30054149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The switch of enzyme therapy in Fabry disease].
    Riccio E; Pisani A
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detailed epitope mapping of neutralizing anti-drug antibodies against recombinant α-galactosidase A in patients with Fabry disease.
    Scharnetzki D; Stappers F; Lenders M; Brand E
    Mol Genet Metab; 2020; 131(1-2):229-234. PubMed ID: 32888778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 27. The utility of the FIPI score in predicting long-term clinical outcomes in patients with Fabry disease receiving enzyme replacement therapy with agalsidase alfa.
    Mac Lochlainn DJ; McKechnie DGJ; Mehta AB; Hughes DA
    Mol Genet Metab; 2018 Feb; 123(2):154-158. PubMed ID: 29055531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
    Pisani A; Riccio E; Sabbatini M
    Genet Med; 2015 Jan; 17(1):21-3. PubMed ID: 25010055
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful desensitization with agalsidase alfa in 2 brothers with Fabry disease.
    Aydin O; Kasapkara CS; Celik GE
    J Investig Allergol Clin Immunol; 2013; 23(5):367-8. PubMed ID: 24260986
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
    Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
    J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
    Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
    Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular and tissue distribution of intravenously administered agalsidase alfa.
    Murray GJ; Anver MR; Kennedy MA; Quirk JM; Schiffmann R
    Mol Genet Metab; 2007 Mar; 90(3):307-12. PubMed ID: 17188539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies.
    Tsurumi M; Suzuki S; Hokugo J; Ueda K
    Expert Opin Drug Saf; 2021 May; 20(5):589-601. PubMed ID: 33599146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy.
    Goker-Alpan O; Longo N; McDonald M; Shankar SP; Schiffmann R; Chang P; Shen Y; Pano A
    Drug Des Devel Ther; 2016; 10():1771-81. PubMed ID: 27307708
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
    Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
    J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generation and Characterization of a Polyclonal Human Reference Antibody to Measure Anti-Drug Antibody Titers in Patients with Fabry Disease.
    Lenders M; Scharnetzki D; Heidari A; Di Iorio D; Wegner SV; Brand E
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol.
    Riccio E; Zanfardino M; Franzese M; Capuano I; Buonanno P; Ferreri L; Amicone M; Pisani A
    Mol Genet Genomic Med; 2021 May; 9(5):e1659. PubMed ID: 33755336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.